Macquarie Group Ltd. Grows Position in Haemonetics Co. (NYSE:HAE)

Macquarie Group Ltd. lifted its stake in Haemonetics Co. (NYSE:HAE) by 8.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,974 shares of the medical instruments supplier’s stock after buying an additional 2,226 shares during the quarter. Macquarie Group Ltd. owned approximately 0.06% of Haemonetics worth $2,480,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Byrne Asset Management LLC lifted its position in Haemonetics by 64.0% during the first quarter. Byrne Asset Management LLC now owns 305 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 119 shares during the last quarter. Meeder Asset Management Inc. lifted its position in Haemonetics by 65.2% during the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 135 shares during the last quarter. State of Wyoming bought a new position in Haemonetics during the fourth quarter valued at $28,000. Signaturefd LLC lifted its position in Haemonetics by 43.9% during the first quarter. Signaturefd LLC now owns 449 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Belpointe Asset Management LLC lifted its position in Haemonetics by 65.5% during the first quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 99.38% of the company’s stock.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $90.00, for a total transaction of $207,450.00. Following the transaction, the executive vice president now owns 14,495 shares of the company’s stock, valued at approximately $1,304,550. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $90.00, for a total value of $207,450.00. Following the sale, the executive vice president now directly owns 14,495 shares in the company, valued at approximately $1,304,550. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Josep Llorens sold 4,928 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $90.00, for a total transaction of $443,520.00. Following the completion of the sale, the executive vice president now owns 18,463 shares in the company, valued at $1,661,670. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,461 shares of company stock valued at $671,638. Company insiders own 1.79% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HAE shares. StockNews.com downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 2nd. Barrington Research increased their target price on shares of Haemonetics from $111.00 to $114.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $103.67.

Haemonetics Trading Up 1.1 %

HAE stock opened at $91.10 on Tuesday. The company has a market capitalization of $4.62 billion, a PE ratio of 34.38, a P/E/G ratio of 2.36 and a beta of 0.41. Haemonetics Co. has a 12 month low of $71.63 and a 12 month high of $95.26. The firm’s 50-day moving average is $89.67 and its 200 day moving average is $85.32. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.38 and a quick ratio of 2.16.

Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, August 8th. The medical instruments supplier reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.32. The business had revenue of $311.30 million for the quarter, compared to the consensus estimate of $292.74 million. Haemonetics had a net margin of 11.21% and a return on equity of 22.49%. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.58 EPS. On average, research analysts anticipate that Haemonetics Co. will post 3.82 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.